Table :	Incidence of Treatment-Emergent Adverse Events Reported in at Least 5% of Subjects in Either Treatment Group, by System Organ Class and Preferred Term (Study XXXXX: Safety Analysis Set - China)
#1||NULL||Drug A (N=143) ||Placebo (N=71)
#1||NULL||Total ||Total
#1||Number of subjects with a treatment-emergent adverse event||136(95.1%)||66(93.0%)
#1||System organ class/preferred term||NULL||NULL
#2||Musculoskeletal and connective tissue disorders||73(51.0%)||37(52.1%)
#3||Bone pain||34(23.8%)||15(21.1%)
#3||Back pain||19(13.3%)||9(12.7%)
#3||Arthralgia||17(11.9%)||5(7.0%)
#3||Pain in extremity||15(10.5%)||10(14.1%)
#3||Musculoskeletal pain||6(4.2%)||5(7.0%)
#2||Metabolism and nutrition disorders||56(39.2%)||22(31.0%)
#3||Hypokalaemia||37(25.9%)||8(11.3%)
#3||Hyperglycaemia||14(9.8%)||4(5.6%)
#3||Decreased appetite||3(2.1%)||9(12.7%)
#2||Investigations||55(38.5%)||27(38.0%)
#3||Weight decreased||4(2.8%)||3(4.2%)
#2||Blood and lymphatic system disorders||39(27.3%)||16(22.5%)
#3||Anaemia||37(25.9%)||16(22.5%)
#2||General disorders and administration site conditions||38(26.6%)||20(28.2%)
#3||Pyrexia||12(8.4%)||3(4.2%)
#3||Fatigue||11(7.7%)||5(7.0%)
#3||Oedema peripheral||10(7.0%)||8(11.3%)
#2||Infections and infestations||33(23.1%)||12(16.9%)
#3||Urinary tract infection||13(9.1%)||6(8.5%)
#3||Upper respiratory tract infection||8(5.6%)||3(4.2%)
#2||Gastrointestinal disorders||32(22.4%)||19(26.8%)
#3||Constipation||11(7.7%)||4(5.6%)
#3||Vomiting||4(2.8%)||6(8.5%)
#2||Vascular disorders||31(21.7%)||10(14.1%)
#3||Hypertension||23(16.1%)||9(12.7%)
#2||Renal and urinary disorders||27(18.9%)||16(22.5%)
#3||Haematuria||8(5.6%)||4(5.6%)

